Leo Pharma looks towards billion-dollar market after phase III success

If everything goes to plan, Leo Pharma will become the second company in the world to lauch a biological drug against eczema. Research director Kim Kjøller has big expectations for the drug, which will compete with Sanofi’s blockbuster drug Dupixent.

Photo: Marcus Trappaud Bjørn/Ritzau Scanpix

Wednesday’s positive data for the eczema drug tralokinumab has given Leo Pharma a pat on the back for its relatively new gamble on biological medicines.

In three different late-stage studies, the company has achieved all primary and secondary effect goals, which is a result that research director Kim Kjøller calls ”incredibly strong”. Leo Pharma is now counting on using this data as a basis for approval applications to health authorities controlling the large markets in the new year.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Latest news

See all jobs